eligibility_summary
Eligibility: Histologically confirmed relapsed/refractory DLBCL, not a candidate for or unwilling to undergo high-dose chemo/autologous SCT and/or unable to receive CAR T. ≥1 prior systemic therapy (phase 2: 1–2), must include anti-CD20. Adequate marrow, hepatic, renal function, ECOG ≤2, provide tumor tissue (fresh/archival). Exclude: prior anti-CD47 or anti-CD19 (non–CAR T) or immunomodulatory agents, prior allo-SCT or auto-SCT <12 weeks, active uncontrolled infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Maplirpacept (PF-07901801/TTI-622) – a CD47-blocking SIRPα–IgG4 Fc fusion protein (innate immune checkpoint inhibitor) that disrupts the CD47 “don’t-eat-me” signal and promotes macrophage phagocytosis, Tafasitamab (Monjuvi) – a humanized, Fc-enhanced anti-CD19 IgG monoclonal antibody that induces ADCC/ADCP and apoptosis of B cells, Lenalidomide (Revlimid) – an oral immunomodulatory small molecule (IMiD) that binds cereblon, degrades IKZF1/3, enhances T/NK-cell activity, and boosts antibody-dependent killing. Targets/pathways: CD19+ malignant B cells, CD47–SIRPα macrophage checkpoint, Fcγ receptor–mediated ADCC/ADCP on NK cells/macrophages, CRBN–IKZF pathway. Goal: synergistic clearance of R/R DLBCL.